First Time Loading...

ImmuCell Corp
NASDAQ:ICCC

Watchlist Manager
ImmuCell Corp Logo
ImmuCell Corp
NASDAQ:ICCC
Watchlist
Price: 5.14 USD 0.78%
Updated: Apr 29, 2024

ImmuCell Corp
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ImmuCell Corp
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
ImmuCell Corp
NASDAQ:ICCC
Operating Income
-$5.7m
CAGR 3-Years
-61%
CAGR 5-Years
-22%
CAGR 10-Years
-76%
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$9.3B
CAGR 3-Years
32%
CAGR 5-Years
2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is ImmuCell Corp's Operating Income?
Operating Income
-5.7m USD

Based on the financial report for Dec 31, 2023, ImmuCell Corp's Operating Income amounts to -5.7m USD.

What is ImmuCell Corp's Operating Income growth rate?
Operating Income CAGR 10Y
-76%

Over the last year, the Operating Income growth was -150%. The average annual Operating Income growth rates for ImmuCell Corp have been -61% over the past three years , -22% over the past five years , and -76% over the past ten years .